Ameritas Investment Partners’s Arbutus Biopharma ABUS Stock Holding History

Ameritas Investment Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.9K	Hold	12,648	–	–	﹤0.01%	2023
2025 Q4	$60.8K	Hold	12,648	–	–	﹤0.01%	1992
2025 Q3	$57.4K	Sell	12,648 -2,808	-18%	-$10.3K	﹤0.01%	2033
2025 Q2	$47.8K	Buy	15,456 +2,832	+22%	+$9.4K	﹤0.01%	2211
2025 Q1	$44.1K	Hold	12,624	–	–	﹤0.01%	2175
2024 Q4	$41.3K	Hold	12,624	–	–	﹤0.01%	2299
2024 Q3	$48.6K	Hold	12,624	–	–	﹤0.01%	2208
2024 Q2	$39K	Buy	12,624 +3,500	+38%	+$10.5K	﹤0.01%	2275
2024 Q1	$23.5K	Hold	9,124	–	–	﹤0.01%	2493
2023 Q4	$22.8K	Hold	9,124	–	–	﹤0.01%	2527
2023 Q3	$18.5K	Hold	9,124	–	–	﹤0.01%	2570
2023 Q2	$21K	Hold	9,124	–	–	﹤0.01%	2543
2023 Q1	$27.6K	Buy	9,124 +3,000	+49%	+$8.46K	﹤0.01%	2326
2022 Q4	$16.9K	Hold	6,124	–	–	﹤0.01%	2635
2022 Q3	$11K	Hold	6,124	–	–	﹤0.01%	2764
2022 Q2	$16K	Hold	6,124	–	–	﹤0.01%	2643
2022 Q1	$18K	Hold	6,124	–	–	﹤0.01%	2597
2021 Q4	$24K	Hold	6,124	–	–	﹤0.01%	2549
2021 Q3	$26K	Hold	6,124	–	–	﹤0.01%	2550
2021 Q2	$19K	Buy	+6,124	New	+$19K	﹤0.01%	2751
2019 Q2	–	Sell	-2,944	Closed	-$11K	–	3045
2019 Q1	$11K	Hold	2,944	–	–	﹤0.01%	2654
2018 Q4	$11K	Hold	2,944	–	–	﹤0.01%	2620
2018 Q3	$28K	Hold	2,944	–	–	﹤0.01%	2324
2018 Q2	$21K	Buy	+2,944	New	+$17.5K	﹤0.01%	2476

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Ameritas Investment Partners's ABUS Position: Q1 2026 in Review

Ameritas Investment Partners held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 12,648 shares worth $56.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

Ameritas Investment Partners first reported a position in ABUS in Q2 2018 and has held it in 24 quarters since. The position peaked at $60.8K in Q4 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Ameritas Investment Partners held 12,648 shares of Arbutus Biopharma worth $56.9K as of Q1 2026.
Ameritas Investment Partners left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2023 holding.
Ameritas Investment Partners first reported a position in Arbutus Biopharma in Q2 2018 and has held it in 24 quarters since.
Ameritas Investment Partners's Arbutus Biopharma position peaked at $60.8K in Q4 2025.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.